Bausch + Lomb (NYSE:BLCO) Price Target Cut to $16.50

Bausch + Lomb NYSEBLCO is a medical device company that operates in the ophthalmic and surgical markets. The company's products include contact lenses, lens care solutions, and surgical instruments.

On Thursday, equities research analysts at Evercore issued a note to investors, stating that they had decreased their price target for Bausch + Lomb NYSEBLCO from $17.00 to $16.50. The firm currently has an "in-line" rating on the stock, which means that it is expected to perform in line with the broader market.

Evercore's new price target for Bausch + Lomb NYSEBLCO represents a potential downside of 6.25% from the current stock price. This suggests that analysts believe the stock may be overvalued and could potentially decline in the near future.

It is important to note that this information is based on the analysis of Evercore's research team, and their opinions are subject to change. Additionally, other factors such as market conditions, company performance, and industry trends can also impact a stock's price. Investors should always conduct their own research and consider seeking advice from financial advisors before making any investment decisions.